Anti-Epileptic drug treatment in children: Hyperhomocysteinaemia, B-Vitamins and the 677C→T Mutation of the Methylenetetrahydrofolate Reductase Gene

The aim of the study was to observe the influence of carbamazepine and valproic acid on plasma total homocysteine and B-vitamin status and the gene–drug interaction with the 677C→T mutation of the methylenetetrahydrofolate reductase (MTHFR) gene. Plasma total homocysteine concentrations were determi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of paediatric neurology 2000, Vol.4 (6), p.269-277
Hauptverfasser:	Vilaseca, M Antònia, Monrós, Eugènia, Artuch, Rafael, Colomé, Catrina, Farré, Carme, Valls, Carme, Cardo, Esther, Pineda, Mercè
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Anticonvulsants - adverse effects Carbamazepine - adverse effects Child Child, Preschool Folic Acid - blood Genotype Homocysteine - blood Humans Hyperhomocysteinaemia, Folate, Vitamin B12, Vitamin B6, MTHFR 677C→T mutation, Anti-epileptic drugs Hyperhomocysteinemia - blood Hyperhomocysteinemia - etiology Infant Methylenetetrahydrofolate Reductase (NADPH2) Mutation - drug effects Oxidoreductases Acting on CH-NH Group Donors - genetics Pyridoxine - blood Valproic Acid - adverse effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The aim of the study was to observe the influence of carbamazepine and valproic acid on plasma total homocysteine and B-vitamin status and the gene–drug interaction with the 677C→T mutation of the methylenetetrahydrofolate reductase (MTHFR) gene. Plasma total homocysteine concentrations were determined in 136 epileptic children taking anti-epileptic drugs as monotherapy. Nutritional (folate, B12and B6vitamins) and genetic (MTHFR 677 C→T) determinants of plasma homocysteine were studied in a random sample of 59 of the 136 epileptic children. Total homocysteine concentrations were significantly increased (p
ISSN:	1090-3798 1532-2130
DOI:	10.1053/ejpn.2000.0379